clinical trial · NCT03904069
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Amgen·phase1·withdrawn
Relapsed/Refractory Acute Myeloid LeukemiaAMG 553
brief summary
Evaluate the safety and tolerability of AMG 553 in adult and adolescent subjects with FLT3-positive R/R AML. Determine the maximum tolerated cell dose (MTCD) or recommended phase 2 cell dose (RP2CD) of AMG 553.
started
Mar 13, 2023
primary completion
Aug 7, 2030
completion
Aug 7, 2030
last updated
Jun 12, 2023
official title
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 Chimeric Antigen Receptor T-cell (CAR-T) AMG 553 in Subjects With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol